Home › Funds › BERNZOTT CAPITAL ADVISORS › HALO

BERNZOTT CAPITAL ADVISORS position in HALO

HALOZYME THERAPEUTICS INC · Health Care

BERNZOTT CAPITAL ADVISORS reported holding 70,403 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q2 2025 13F filing — a position valued at US$3.7M, representing 1.87% of its reported portfolio and ranking #30 among its reported holdings. BERNZOTT CAPITAL ADVISORS has disclosed HALO holdings in 7 of the last 8 reported quarters, going back to Q3 2023.

Latest position (Q2 2025)70.40K sh
Reported value held$3.66M
Portfolio Weight1.87%
First reportedQ3 2023
Last changeReduce
Updated2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

How BERNZOTT CAPITAL ADVISORS's HALO position evolved

BERNZOTT CAPITAL ADVISORS first disclosed a stake in HALO in Q3 2023 at 171,808 shares (US$6.6M). The position peaked in Q2 2024 at 187,249 shares, worth US$9.8M. Across 7 filings, BERNZOTT CAPITAL ADVISORS increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2025) shows 70,403 shares valued at US$3.7M — a reduction of -31,357 shares quarter over quarter.. Notable position changes include a 27% trim in Q4 2023 (shares rose 10% over the following quarter), a 68% increase in Q1 2024 (shares rose 29% over the following quarter), a 31% trim in Q2 2025 (shares rose 41% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 171.81K $6.56M New
Q4 2023 124.98K $4.62M Reduce
Q1 2024 209.80K $8.53M Add
Q2 2024 187.25K $9.80M Reduce
Q4 2024 93.98K $4.49M New
Q1 2025 101.76K $6.49M Add
Q2 2025 70.40K $3.66M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About HALO and 13F data

HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 43 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$196.5M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding HALO

All HALO fund holders →

FAQ

How long has BERNZOTT CAPITAL ADVISORS held HALO?

BERNZOTT CAPITAL ADVISORS has disclosed HALO holdings in 7 of the last 8 reported quarters, going back to Q3 2023.

What is BERNZOTT CAPITAL ADVISORS's current position in HALO?

As of Q2 2025, BERNZOTT CAPITAL ADVISORS holds 70.40K shares of HALO (HALOZYME THERAPEUTICS INC), valued at $3.66M, representing 1.87% of its reported portfolio and ranking #30.

Has BERNZOTT CAPITAL ADVISORS been buying or selling HALO?

In the latest 13F filing (Q2 2025), BERNZOTT CAPITAL ADVISORS reduced its position in HALO. The position peaked in Q2 2024 at 187.25K shares.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, SNYDER CAPITAL MANAGEMENT L P, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.